SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

SG Americas Securities LLC increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 104.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,839 shares of the company’s stock after acquiring an additional 4,506 shares during the period. SG Americas Securities LLC’s holdings in Dianthus Therapeutics were worth $242,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bain Capital Life Sciences Investors LLC bought a new position in shares of Dianthus Therapeutics in the 1st quarter worth $89,761,000. RA Capital Management L.P. bought a new position in shares of Dianthus Therapeutics during the 1st quarter valued at $69,990,000. Great Point Partners LLC grew its holdings in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Dianthus Therapeutics during the 1st quarter valued at $11,251,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $28.38 on Tuesday. The firm has a market cap of $832.92 million, a P/E ratio of -4.87 and a beta of 1.85. Dianthus Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The firm has a 50-day simple moving average of $27.80 and a two-hundred day simple moving average of $26.09.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.28 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on DNTH shares. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Thursday, September 26th. Oppenheimer started coverage on shares of Dianthus Therapeutics in a research report on Thursday, October 3rd. They set an “outperform” rating and a $48.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating for the company. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, Wedbush dropped their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $45.13.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.